Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CDIO
stocks logo

CDIO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
75.00K
+852.99%
-1.800
-0%
150.00K
+2179.64%
-1.800
-0%
250.00K
+5443.24%
-1.800
+500%
Estimates Revision
The market is revising No Change the revenue expectations for Cardio Diagnostics Holdings, Inc. (CDIO) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -18.06%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-18.06%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Cardio Diagnostics Holdings Inc (CDIO.O) is -0.44, compared to its 5-year average forward P/E of -4.03. For a more detailed relative valuation and DCF analysis to assess Cardio Diagnostics Holdings Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.03
Current PE
-0.44
Overvalued PE
1.44
Undervalued PE
-9.50

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
91.65
Current PS
0.00
Overvalued PS
277.04
Undervalued PS
-93.74
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

CDIO News & Events

Events Timeline

(ET)
2025-12-03
08:50:00
Cardio Diagnostics Sets Final Payment Rate of $854 for Epi+Gen CHD and PrecisionCHD Tests
select
2025-07-22 (ET)
2025-07-22
09:13:48
Cardio Diagnostics gets CMS gapfill payment rates for cardiovascular tests
select
2025-07-08 (ET)
2025-07-08
09:17:19
Cardio Diagnostics, AGEPHA Pharma in deal for heart disease study
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
11-05Newsfilter
Cardio Diagnostics Holdings, Inc. to Showcase Data Highlighting PrecisionCHD's Capability to Identify INOCA and MINOCA at the American Heart Association Scientific Sessions

  • Underdiagnosed Heart Conditions: Ischemia with No Obstructive Coronary Arteries (INOCA) and Myocardial Infarction with No Obstructive Coronary Arteries (MINOCA) are significant yet often undetected forms of heart disease, affecting a large number of patients, particularly women.

  • PrecisionCHD Test Presentation: Cardio Diagnostics will present new data at the AHA Scientific Sessions showcasing how their PrecisionCHD test, which utilizes epigenetic biomarkers, can effectively detect INOCA and MINOCA, providing a noninvasive diagnostic tool.

  • Research Findings: A study conducted with the University of Iowa demonstrated that DNA methylation markers in the PrecisionCHD test can sensitively and specifically identify INOCA presentations, offering personalized insights for patient care.

  • Advancing Cardiovascular Medicine: Cardio Diagnostics aims to revolutionize cardiovascular diagnostics through their AI-driven technology, making detection and management of heart disease more accessible and tailored to individual patient needs, especially for underserved populations.

[object Object]
Preview
7.5
10-28Newsfilter
Cardio Diagnostics Holdings, Inc. Teams Up with YMCA of East Tennessee to Provide Heart Health Education and Advanced Testing for the Local Community

  • Partnership Announcement: Cardio Diagnostics is partnering with the YMCA of East Tennessee to offer a customized program for its members, which includes educational sessions called "Wisdom Wednesdays" and discounted access to AI-powered cardiovascular tests.

  • Heart Disease Statistics: Heart disease is the leading cause of death in the U.S., with Tennessee having a notably high cardiovascular mortality rate, highlighting the importance of early detection and prevention initiatives.

  • Educational Initiatives: The program will feature six educational sessions starting in November 2025, focusing on coronary heart disease prevention and proactive heart health management.

  • Community Access: The collaboration aims to extend cardiovascular testing and educational resources beyond YMCA members to the entire East Tennessee community, promoting heart health awareness and proactive measures.

[object Object]
Preview
7.5
10-21Newsfilter
Cardio Diagnostics Holdings, Inc. Grows Provider Network with Addition of 15 New Organizations Nationwide

  • Expansion of Partnerships: Cardio Diagnostics has partnered with 15 new provider organizations across the U.S., showcasing the growing adoption of their AI-driven precision cardiovascular medicine tests, Epi+Gen CHD™ and PrecisionCHD™.

  • Diverse Care Models: The new partnerships span various medical specialties and care models, including concierge, functional medicine, and primary care practices, emphasizing personalized and preventive healthcare approaches.

  • Innovative Testing Technology: The integration of Epi+Gen CHD™ and PrecisionCHD™ allows providers to gain actionable insights into coronary heart disease and heart attack risk, enhancing patient care and treatment plans.

  • Mission for Accessibility: Cardio Diagnostics aims to make precision cardiovascular medicine more accessible, addressing the rising prevalence of cardiovascular disease and improving early detection and management across diverse patient populations.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Cardio Diagnostics Holdings Inc (CDIO) stock price today?

The current price of CDIO is 3.04 USD — it has increased 5.56 % in the last trading day.

arrow icon

What is Cardio Diagnostics Holdings Inc (CDIO)'s business?

Cardio Diagnostics Holdings, Inc. is an artificial intelligence-powered precision cardiovascular medicine company. The Company develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development, and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.

arrow icon

What is the price predicton of CDIO Stock?

Wall Street analysts forecast CDIO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CDIO is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Cardio Diagnostics Holdings Inc (CDIO)'s revenue for the last quarter?

Cardio Diagnostics Holdings Inc revenue for the last quarter amounts to 2.86K USD, decreased -56.61 % YoY.

arrow icon

What is Cardio Diagnostics Holdings Inc (CDIO)'s earnings per share (EPS) for the last quarter?

Cardio Diagnostics Holdings Inc. EPS for the last quarter amounts to -0.98 USD, decreased -43.35 % YoY.

arrow icon

What changes have occurred in the market's expectations for Cardio Diagnostics Holdings Inc (CDIO)'s fundamentals?

The market is revising No Change the revenue expectations for Cardio Diagnostics Holdings, Inc. (CDIO) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -18.06%.
arrow icon

How many employees does Cardio Diagnostics Holdings Inc (CDIO). have?

Cardio Diagnostics Holdings Inc (CDIO) has 13 emplpoyees as of December 05 2025.

arrow icon

What is Cardio Diagnostics Holdings Inc (CDIO) market cap?

Today CDIO has the market capitalization of 5.66M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free